Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vertex Pharmaceutic 50 NORTHERN AVENUE BOSTON MA 02210 USA

www.vrtx.com Employees: 6,100 P: 617-341-6100

Sector:

Medical

Description:

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.

Key Statistics

Overview:

Market Capitalization, $K 111,981,408
Enterprise Value, $K 107,411,808
Shares Outstanding, K 253,719
Float, K 253,212
% Float 99.80%
Short Interest, K 5,022
Short Float 1.98%
Days to Cover 4.09
Short Volume Ratio 0.35
% of Insider Shareholders 0.20%
% of Institutional Shareholders 90.96%

Financials:

Annual Sales, $ 11,020 M
Annual Net Income, $ -535,600 K
Last Quarter Sales, $ 3,076 M
Last Quarter Net Income, $ 1,083 M
EBIT, $ 3,993 M
EBITDA, $ 4,201 M

Growth:

1-Year Return 4.76%
3-Year Return 37.53%
5-Year Return 92.98%
5-Year Revenue Growth 164.73%
5-Year Earnings Growth -131.47%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 4.80 on 11/03/25
Next Earnings Date 02/09/26 [--]
Earnings Per Share ttm 15.31
EPS Growth vs. Prev Qtr 5.50%
EPS Growth vs. Prev Year 4.46%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 08/24/00

VRTX Ratios

Ratio
Price/Earnings ttm 28.67
Price/Earnings forward 25.17
Price/Earnings to Growth N/A
Return-on-Equity % 23.51%
Return-on-Assets % 16.80%
Profit Margin % -4.86%
Debt/Equity 0.00
Price/Sales 9.74
Price/Cash Flow N/A
Price/Book 6.53
Book Value/Share 67.55
Interest Coverage 9.12
60-Month Beta 0.31
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar